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Abstract
Background: Detergent-insoluble protein accumulation and aggregation in the brain is one of the pathological
hallmarks of neurodegenerative diseases. Here, we describe the identification of septin 11 (SEPT11), an enriched
component of detergent-resistant fractions in frontotemporal lobar degeneration with ubiquitin-immunoreactive
inclusions (FTLD-U), using large-scale unbiased proteomics approaches.
Results: We developed and applied orthogonal quantitative proteomic strategies for the unbiased identification of
disease-associated proteins in FTLD-U. Using these approaches, we proteomically profiled detergent-insoluble
protein extracts prepared from frontal cortex of FTLD-U cases, unaffected controls, or neurologic controls (i.e.
Alzheimer’s disease; AD). Among the proteins altered specifically in FTLD-U, we identified TAR DNA binding
protein-43 (TDP-43), a known component of ubiquitinated inclusions. Moreover, we identified additional proteins
enriched in detergent-resistant fractions in FTLD-U, and characterized one of them, SEPT11, in detail. Using
independent highly sensitive targeted proteomics approaches, we confirmed the enrichment of SEPT11 in FTLD-U
extracts. We further showed that SEPT11 is proteolytically cleaved into N-terminal fragments and, in addition to its
prominent glial localization in normal brain, accumulates in thread-like pathology in affected cortex of FTLD-U
patients.
Conclusions: The proteomic discovery of insoluble SEPT11 accumulation in FTLD-U, along with novel pathological
associations, highlights a role for this cytoskeleton-associated protein in the pathogenesis of this complex disorder.
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Background
Frontotemporal lobar degeneration (FTLD) encompasses
a heterogeneous group of sporadic and familial diseases
associated with circumscribed degeneration of the pre-
frontal and anterior temporal lobes. As the third most
common neurodegenerative cause of dementia behind
Alzheimer’s disease (AD) and Lewy body dementia,
FTLD accounts for 5% of dementia cases irrespective of
age [1]. Pathologically, FTLD is equally heterogeneous,
and may present as a tauopathy, or more commonly,
with tau-negative, ubiquitin-immunoreactive neurites
and inclusions [2]. In these cases, termed FTLD-
ubiquitin (FTLD-U), histopathology is primarily
observed within the small layer II neurons of the frontal
and temporal cortices, as well as in granule cells of the
dentate gyrus of the hippocampus [3].
In recent years, significant progress has been made in
understanding the genetic and neuropathologic basis of
FTLD-U. In 2006, mutations in the progranulin gene
(GRN) were identified as the cause of chromosome 17-
linked FTLD-U [4,5]. This discovery was followed by the
identification of TAR DNA-binding protein 43 (TDP-
43), the first major non-ubiquitin protein component of
pathological inclusions in familial and sporadic FTLD-U
[6]. Although in normal neurons TDP-43 is a nuclear
RNA-binding protein, in pathologic conditions TDP-43
redistributes from the nucleus to the cytoplasm where it
is aggregated, phosphorylated, ubiquitinated, and
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Notably, TDP-43 is also localized in the intracytoplasmic
ubiquitinated inclusions of sporadic amyotrophic lateral
sclerosis (ALS), a motor neuron disease often associated
with FTLD-U [3,6], and mutations in TDP-43 have been
linked to ALS [7-10].
The molecular pathways underlying TDP-43 aggrega-
tion and toxicity have not yet been fully elucidated.
Fragmentation of TDP-43, possibly by caspase-depen-
dent cleavage [11], and its subsequent cytoplasmic
sequestration have been posited as critical factors in
promoting cellular toxicity [12,13]. However, several
reports have questioned the specificity of the association
between TDP-43 and FTLD-U/ALS after TDP-43
immunoreactive aggregates were found in a range of
neurodegenerative disorders, including AD and Parkin-
son’s disease (PD) [14,15]. In addition, extensive histo-
pathological characterization of FTLD-U cases with
TDP-43 specific antibodies has revealed at least four
pathologic FTLD-U subtypes that differ in aggregate dis-
tribution, density, and morphology, suggesting that they
may not share a common molecular basis [16,17].
Finally, cases caused by mutations in the CHMP2B
gene, as well as sporadic cases with FUS-immunoreac-
tive inclusions, feature ubiquitin-positive inclusions that
lack TDP-43 immunoreactivity [18,19]. Taken together,
these findings suggest that other, as yet unknown, pro-
teins may contribute in the pathogenesis of this complex
disorder. Thus, in the current study we applied quantita-
tive proteomics methodologies to identify molecular
substrates and pathways involved in FTLD-U pathogen-
esis. Application of these strategies in performing shot-
gun proteomic analyses of FTLD-U samples resulted in
the identification of SEPT11, a novel FTLD-U-associated
protein that is enriched in detergent-insoluble fractions
and accumulates in the brain of FTLD-U cases.
Results and Discussion
Discovery of altered proteins in FTLD-U by LC-MS/MS
To identify differentially expressed proteins in FTLD-U,
which like TDP-43 are enriched in detergent-insoluble
brain fractions, we examined post-mortem samples
using two independent shotgun quantitative proteomic
approaches (Figure 1a-b). In the first strategy, frontal
cortex homogenates from 10 cases each of FTLD-U,
AD, and control (Table 1) were pooled by diagnosis and
serially extracted with buffers of increasing stringency.
To allow estimation of the variances associated with
sample preparation and analysis, the FTLD-U pooled
homogenates were divided into two identical samples
and processed in parallel as technical replicates. The
resulting four detergent-insoluble, urea-soluble fractions
were first separated by SDS-PAGE (Additional File 1a),
excised in 5 bands from the gel, trypsin digested, and
analyzed via liquid chromatography coupled with tan-
dem mass spectrometry (LC-MS/MS) on a high resolu-
tion mass spectrometer. For each of the 512 identified
proteins, a quantitative protein comparison based on the
extracted ion current (XIC) of individual peptides was
performed, and abundance ratios calculated (e.g. FTLD-
U/Control). To statistically evaluate and filter the quan-
titative data, the abundance ratios from all pair-wise
comparisons were logarithmically transformed and the
resulting histogram of all values was fitted to a Gaussian
distribution (Additional Files 2 and 3). In all, 50 proteins
were found to be significantly altered in FTLD-U when
compared to control and AD extracts.
To reduce the variances in the proteomics analysis, we
performed an independent study using a separate MS
strategy based on the use of culture-derived isotopic
tags (CDIT), and cross-referenced the findings with the
first label-free approach [20]. In this second approach,
whole cell lysate from isotopically-labeled HEK 293 cells
was mixed equally with urea-soluble fractions prepared
from pools of 4 FTLD-U or 4 control cases (Table 1
marked by asterisk). The heavy-labeled peptides from
the cell lysate are chemically identical to their unlabeled
counterparts in each urea fraction, and can therefore
serve as internal standards for the measurement of pro-
tein abundance across samples [21]. The urea/HEK 293
lysate mixtures were subsequently separated by SDS-
PAGE (Additional File 1b) and also excised in 5 bands
for LC-MS/MS analysis. Using the heavy-labeled internal
standard as a reference between FTLD-U and control
samples, abundance ratios were calculated, converted
into log2 v a l u e s ,p l o t t e da sah i s t o g r a mo fa l lp r o t e i n s ,
and fitted to a Gaussian distribution (Additional File 4).
Of the 1304 proteins identified in this approach, 194
were found to be altered in FTLD-U compared with
control. Among the 10 proteins significantly altered in
both proteomic discovery sets (Table 2), we identified
Septin 11 (SEPT11), a 429 amino acid cytoskeletal
GTPase thought to play a role in filament formation
[22]. SEPT11 was consistently enriched ~4-fold in
FTLD-U compared to control across all molecular
weight regions in both proteomics experiments. In the
label-free approach, we identified 3 SEPT11 peptides
(Additional File 5), and quantification revealed a total
signal to noise ratio (SN) of 19.9 in both FTLD-U repli-
cates compared with 4.6 in the control sample. Similarly,
we identified the same 3 peptides in the CDIT strategy,
as well as an additional peptide, with total SN of 134.4
in FTLD-U and 43.4 in control. As expected, TDP-43
was also increased in FTLD-U, albeit more modestly
than SEPT11, showing ~1.8-fold and ~1.3-fold enrich-
ment in the label-free and CDIT quantitative proteomics
approaches, respectively. The specificity of our proteo-
mics strategy was further validated by comparison with
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Page 2 of 13Figure 1 Diagram of experimental workflow. (a) Sample preparation for label-free quantitative proteomics (Discovery Phase A). Ten cases
each of AD, FTLD-U, and Control were pooled by diagnosis and sequentially extracted. Urea samples were then analyzed by shotgun LC-MS/MS.
(b) Sample preparation for quantitative proteomics based on culture derived isotopic tags (Discovery Phase B). Four cases each of FTLD-U and
control were pooled by diagnosis and sequentially extracted. Urea fractions for each diagnosis were mixed (1:1) with HEK293 lysate labeled with
heavy stable isotopes of arginine and lysine. The heavy labeled peptides served as internal standards following analysis by LC-MS/MS. (c)
Validation of identification of Septin 11 enrichment in FTLD-U using three independent methods.
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Page 3 of 13Table 1 Detailed Demographics of Cases Selected for Proteomics
Diagnosis Case #
1PMI (hr) Age at Death Duration ApoE Status
2Race/Sex
1 4 55 6 E3/3 W/M
2 4.5 55 3 E3/4 W/F
3 20 57 7 E3/4 B/F
4 11.5 62 10 E3/4 W/M
AD 5 4.5 64 12 E3/4 W/F
6 5.5 69 21 E4/4 W/F
7 15 71 2.5 E3/4 W/M
8 17 71 8 E3/4 W/M
9 21 76 12 E2/3 W/F
10 12 81 12 E3/4 W/F
n = 10 AVG 11.5 66.1 9.4
1 3 52 E3/4 W/F
2 10 57 E3/3 W/M
3
3* 8 60 E3/4 B/F
4 12 61 E3/4 B/M
Control 5 12 65 NA E3/3 W/M
6 6 65 E3/3 W/F
7 * 11 68 E3/3 W/F
8 * 6 69 E3/3 W/M
9 7 74 E3/3 W/F
10 * 6 75 E3/3 W/F
n = 10 AVG 8.1 64.6 NA
1 3 41 9 E3/3 W/M
2 17.5 61 5 E3/3 W/M
3 * 11.5 62 10 E3/3 A/F
4 * 17 63 7.5 E3/3 W/M
FTLD-U 5 6 64 8 E3/4 W/F
6 * NA 69 1 E3/3 W/F
7 NA 69 1 E3/3 W/F
8 18 71 9 E3/3 W/F
9 17 74 16 E3/4 W/M
10 * 7 83 4 E3/3 W/F
n = 10 AVG 12.1 65.7 7.1
1Post-mortem interval
2White, Black, Asian, Female, Male
3Cases marked with asterisk were selected for pooling in CDIT proteomics.
Table 2 Proteins specifically altered in FTLD-U urea fractions using two independent proteomics strategies.
GeneBank™ Label-Free Approach CDIT Approach
Protein Accession Number mean Log2 Ratio Log2 Ratio
FTLD-U/Control FTLD-U/AD FTLD-U/Control
Septin 11 NP_060713.1 2.0 2.4 1.8
Excitatory Amino Acid Transporter 2 NP_004162.2 2.0 1.5 4.2
Glial Fibrillary Acidic Protein NP_002046.1 1.9 1.3 2.2
Alpha Catenin NP_001894.2 1.3 1.3 3.9
Aquaporin 4 NP_004019.1 1.1 0.9 10.1
Protein Phosphatase 2 NP_055040.2 1.0 1.2 1.8
Transketolase NP_001055.1 0.9 1.1 2.2
2,4-Dienoyl CoA Reductase 2 NP_065715.1 -1.1 -0.9 -3.2
Rho GTPase Activating Protein 1 NP_004299.1 -1.5 -1.0 -1.6
Synaptosomal-Associated Protein 25 NP_003072.2 -1.5 -1.0 -4.9
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Page 4 of 13AD cases, as SEPT11 was not correspondingly increased
in insoluble material from AD frontal cortex. This find-
ing indicates that the enrichment of SEPT11 in FTLD-U
is not a non-specific association with protein aggregates,
and that it is distinct from proteins associated with neu-
rofibrillary tangles and senile plaques. Moreover, known
AD-associated proteins, including b-amyloid, tau, and
apolipoprotein E, were all enriched in insoluble fractions
in AD cases but not in FTLD-U [23].
Validation of SEPT11 enrichment in FTLD-U
Septins are a highly conserved family of filamentous
proteins first identified in yeast as a group of cell divi-
sion cycle regulatory genes [24]. The 14 mammalian
septins identified to date share a central characteristic
P-loop GTP-binding domain flanked N- and C-termini
which vary in length and amino acid composition [25].
Based on their amino acid sequence homology and their
capacity to interchange with other septins in hetero-
meric complexes that underlie filament assembly, mam-
malian septins can be further classified into four
subgroups. SEPT11 belongs to the septin 6 (SEPT6)
subfamily, which along with other subgroup members
(septins 8 and 10) may provide for redundancy in the
formation of the septin 2/6/7 and 7/9b/11 filamentous
complexes [22,26]. SEPT11 and SEPT6 share 85%
homology, and both are expressed in the CNS [27-29].
Therefore, to confirm the proteomic identification of
SEPT11 in FTLD-U urea fractions, we first used a tar-
geted mass spectrometry approach to map unique
SEPT11 peptides in SEPT11-overexpressing HEK 293
cells. We subsequently selected 5 of these unique pep-
tides and validated their presence in urea fractions pre-
pared from 4 pooled FTLD-U cases (Additional File 6).
Finally, we re-quantified SEPT11 at its expected molecu-
lar weight (Gel piece 3; 40-60 kDa) in the pooled urea
samples containing the heavy-labeled SEPT11 HEK 293
cell lysate. Specifically, we monitored multiple high
intensity product ions, which serve as surrogates for
measurement of peptide intensities, from two unique
peptides corresponding to amino acids 66-79 and 400-
4 1 8( F i g u r e2 ) .S E P T 1 1w a se n r i c h e d2 . 1 - f o l d( ±0 . 2 )i n
FTLD-U compared to control in this gel band (Table 3).
In contrast, concurrent examination of 3 b-actin pep-
tides revealed a slight reduction of this reference protein
in FTLD-U samples (0.7 ± 0.1).
The 2-fold discrepancy in SEPT11 enrichment obtained
via the shotgun proteomics analyses and the highly sen-
sitive and specific targeted proteomics strategy, suggests
that SEPT11 may also be enriched in additional molecu-
lar weight regions. Stratification of the data obtained in
the proteomic approach using CDIT by molecular
weight demonstrated widespread distribution of SEPT11
peptides throughout the entire mass range, with spectra
identified in every gel band. Quantitation using XIC and
the heavy-labeled internal standard showed a 1.6 to 2-
fold enrichment of SEPT11 at the 40-60 kDa range,
with higher and lower molecular weight regions
accounting for the remainder of the ~4-fold change in
these samples. To confirm the changes observed by
mass spectrometry, we performed immunoblots on
FTLD-U and control urea fractions using a rabbit poly-
clonal antibody raised to a peptide (amino acids 1-15) at
the extreme N-terminus of SEPT11 (Figure 3). In addi-
tion to the expected band at 49 kDa corresponding to
the full length protein, we detected 3 specific SEPT11-
immunoreactive bands at ~45 kDa, ~37 kDa, and ~28
kDa in FTLD-U urea fractions that were absent or
reduced in control extracts (Figure 3c) and in the corre-
sponding detergent-soluble fractions (Additional File 7).
Quantification of immunoblot band intensities showed a
m o d e s tb u ts i g n i f i c a n t1 . 8 - f o l de n r i c h m e n t( p = 0.006)
of the full-length SEPT11 band in frontal cortex urea
fractions from 7 FTLD-U and 9 control cases (Figure
3d), supporting the quantitative mass spectrometric
measurements at this molecular weight. Moreover,
SEPT11 lower Mr fragments were 3.1-fold enriched in
these FTLD-U cases compared to controls (p < 0.001).
The proteolytic cleavage of SEPT11 is consistent with
that observed for other pathologic aggregating proteins,
including TDP-43 and tau, where polymerization, post-
translational modification, and degradation underlie pro-
tein insolubility [6,30].
To examine if the SEPT11 biochemical insolubility
reflects an altered distri b u t i o ni nF T L D - U ,w ep e r -
formed immunohistochemical analysis using our specific
N-terminal polyclonal antibody. SEPT11 immunoreac-
tivity was localized with astrocytic cell bodies and pro-
cesses in frontal cortex of FTLD-U and control cases
(Figure 4a-b). Moreover, we observed neuropil immu-
noreactivity consistent with the localization of SEPT11
along dendrites and in post-synaptic membranes as has
been previously described [31]. Analysis revealed no
SEPT11 overlap with TDP-43 and ubiquitin-positive
neuronal inclusions. However, in a subset of FTLD-U
cases, we identified numerous fibrillar thread-like struc-
tures which did not associate with glial processes or
nuclei (Figure 4c-e). These SEPT11-immunoreactive fea-
tures localized primarily in superficial cortical layers
(layers 2-3), and appeared irregular in shape, length, and
thickness. Antibody specificity was confirmed using pep-
tide competition studies, resulting in the complete loss
of immunoreactivity in glia, neuropil, and pathologic
threads. In contrast, we were unable to preadsorb a
thread-like pathology seen with a separate commercially
available SEPT11 antibody.
To determine whether SEPT11 threads correspond to
a disease-specific signature, we examined and scored
Gozal et al. Molecular Neurodegeneration 2011, 6:82
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Page 5 of 13Figure 2 Targeted proteomics to quantify SEPT11 enrichment in urea fractions.( a )M S / M Ss c a no ft h ep r e c u r s o ri o n( m/z 979.0)
corresponding to a unique SEPT11 peptide (amino acids 400-418). (b) MS/MS product ions selected for quantitation in light (top) and heavy
(bottom) peptide forms. (c) Extracted ion chromatogram of targeted spectra for each of the product ions in (b). The spiked heavy- (red) and
endogenous light (black) peptides have identical retention times and are overlaid. For each product ion, enrichment is calculated as a ratio of
light to heavy signal of the area under each curve.
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Page 6 of 13this characteristic staining in a series of FTLD-U, ALS,
neurologic disease control (AD, PD, and tauopathies),
and normal control cases in a blinded fashion using a
semi-quantitative 4-tiered rating scale (Additional File
8). SEPT11 threads were markedly enriched in FTLD-U,
with 56% of cases (9/16) scored as having positive or
very positive (score ≥ 2) staining of threads (Figure 4f).
In comparison, only 18% (7/39; p = 0.008) of neurologic
controls and 22% (4/18; p = 0.076) of normal controls
were scored in this range. Moreover, when FTLD-U and
ALS, the two disease groups associated with TDP-43,
were examined together and compared to the TDP-43
negative neurologic controls (AD, PD, and tauopathies),
t h ed i f f e r e n c ei nS E P T 1 1p a t h o l o g yw a se v e ns t r o n g e r
(p < 0.001). This provided additional support for shared
pathogenic mechanisms in FTLD-U and ALS. Since
t h e i rp r e s e n c ei sh i g h l ys p e c i f i ct oF T L D - Ua n dA L S ,
SEPT11-immunoreactive threads may reflect pathologic
accumulations of the insoluble full-length or fragmented
protein identified in urea fractions.
Conclusions
Perturbed expression of septins, a family of cytoskeletal
GTP-binding proteins, has been extensively associated
with neurodegeneration. Notably, SEPT1, SEPT2, and
SEPT4 have been shown to co-localize with neurofibril-
lary tangles and dystrophic neurites in AD [32]. In PD,
SEPT4 co-localizes with a-synuclein in Lewy bodies
[33], and SEPT5 has been shown to be a target for par-
kin-mediated ubiquitination [34]. In this study, we have
shown that SEPT11 is biochemically altered and accu-
mulates in FTLD-U. Although the specific functions of
SEPT11 in the brain are not well defined, SEPT11 is
thought to form multi-septin complexes that assemble
into filaments and function as scaffolds for cytoskeletal-
binding proteins [35]. Supporting this potential role,
SEPT11 has been shown to colocalize with microtubules
and stress fibers in multiple epithelial cell lines [36].
Thus, it is plausible that changes in SEPT11 solubility
could disrupt cytoskeletal function and result in cellular
toxicity, a mechanism already established for tau-based
proteopathies in other neurodegenerative disorders [37].
In fact, SEPT11 insolubility and toxicity may be related
to the presence of lower Mr fragments in FTLD-U urea
fractions identified by immunoblotting (Figure 3). This
would parallel findings in a highly homologous protein,
SEPT6, in which N-terminal fragments containing the
variable region and GTP-binding domain have been
reported to be insoluble [38]. As is seen with multiple
disease proteins, including TDP-43, tau, a-synuclein,
and Ab [39,40], proteolytic cleavage of SEPT11 may
result in protein misfolding, aggregation, and cytotoxi-
city. Finally, truncation of the SEPT11 C-terminus
would also impact the coiled-coil domain of the protein,
a region critical for septin-septin interactions as well as
for binding to non-septin partners [31,38].
Our characterization of SEPT11 in FTLD-U estab-
lishes a powerful approach to large-scale identification
of disease-associated proteins in neurodegenerative con-
ditions through analysis of the detergent-insoluble pro-
teome. SEPT11 immunoreactive threads are a novel
neuropathological feature of a subgroup of FTLD-U
cases, but accumulation of insoluble SEPT11 aggregates
is not a universal feature of all FTLD-U cases. Our
Table 3 Targeted MS conditions for Septin11 peptides in gel band corresponding to 40-60 kDa.
1Precursor Ions (m/z)
5Product Ions (m/z)
6AUC (FTLD-U) AUC (Control) FTLD-U/Control
Protein Name Peptide Sequences
Native (
2L)
3IS (
4H) Name Native (L) IS (H) (L) (H) (L) (H)
Septin11 FESDPATHNEPGVR 778.4 783.4
y2-10 539.4 544.4 2420 1034 1776 1531 2.0
y1-10 1077.3 1087.3 5428 1176 3548 1797 2.3
Septin11 AAAQLLQSQAQQSGAQQTK 979.0 983.0
y1-7 719.3 727.3 2700 790 1747 921 1.8
y1-10 1046.4 1054.4 2242 743 1559 1030 2.0
y1-12 1261.6 1269.6 3476 1074 1790 1334 2.4
2.1 ± 0.2
Precursor Ions (m/z)
7XIC (FTLD-U) XIC (Control)
Native (L) IS (H) (L) (H) (L) (H)
b-actin AGFAGDDAPR 488.73 493.74 3208 916 3799 717 0.7
b-actin GYSFTTTAER 566.77 571.78 2651 740 4109 896 0.8
b-actin SYELPDGQVITIGNER 895.96 900.96 2474 704 2806 584 0.7
0.7 ± 0.1
1The m/z values of native and labeled peptides
2Light
3Internal Standard
4Heavy
5The name and m/z values of monitored product ions (e.g. y1-7, the singly-
charged y7 ion)
6Area under the curve
7Extracted ion chromatogram.
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Page 7 of 13Figure 3 Immunoblots of SEPT11 confirm proteomic findings. (a) Frontal cortex samples from individual FTLD-U and control cases were
sequentially extracted with buffers containing triton X-100, sarkosyl, and urea. Urea fractions were immunoblotted with an affinity purified
SEPT11 rabbit polyclonal antibody raised to a peptide at the extreme N-terminus. (b) Preabsorption using the immunizing peptides quenches
immunoreactivity with the exception of a faint non-specific band at ~40 kDa. (c) Overexposed immunoblot of urea fractions from additional
FTLD-U and control cases detects SEPT11 at its expected Mr (49 kDa), as well as additional N-terminal species at ~45 kDa, ~37 kDa, and ~28 kDa.
(D) Quantification in 7 FTLD-U cases and 9 controls of immunoblot band intensities for 49 kDa band (top panel) and all 3 SEPT11 lower Mr
fragments (bottom panel). The band at ~40 kDa that did not preabsorb in (b) was excluded from the analysis.
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Page 8 of 13Figure 4 SEPT11 immunoreactivity in control and FTLD-U using polyclonal N-terminal antibody. (a-b) Double label immunofluorescence
in control (a) and FTLD-U (b) frontal cortex reveals overlap between SEPT11 (red) and glial fibrillary acidic protein (GFAP; green), suggesting that
cell-associated staining localizes to astrocyte cell bodies and processes. (c-e) IHC in FTLD-U (d and e) frontal cortex detects both linear and
rounded accumulations of SEPT11 that are absent in control (c). Unlike in (a) and (b), these SEPT11 threads were not associated with specific cell
bodies. (f) Summary of blinded scoring of frontal cortex from 81 cases and controls for the presence of SEPT11 threads.
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Page 9 of 13proteomics-based strategy incorporated pooled samples
of FTLD-U and control cases to reduce the impact of
biological variability that is unavoidable and uncontrolla-
ble in studies of human autopsy materials. Factors, such
as postmortem interval, unknown agonal circumstances,
and other individual features unique to every patient,
introduce enormous noise in efforts to identify disease-
specific elements. Although accepted criteria for FTLD-
U have been established, our understanding of this neu-
ropathological entity is far from complete. This is clearly
demonstrated by ongoing efforts to subclassify FTLD-U
cases based on specific features of TDP-43 immunoreac-
tivity. We have now shown that pathological accumula-
tion of SEPT11 in superficial cortical layers defines an
additional molecular feature linked to FTLD-U, and clo-
ser examination of candidates identified through proteo-
mic profiling will reveal additional features that will
produce a clearer understanding of this complex neuro-
degenerative disorder.
Methods
Case Material
Post-mortem human brain tissues corresponding to
diagnoses of FTLD-U, AD, PD, ALS, tauopathy, and
unaffected control were obtained from the Alzheimer’s
Disease Research Center (ADRC) and Center for Neuro-
degenerative Disease (CND) Brain Bank at Emory Uni-
versity School of Medicine. Diagnoses of FTLD-U, AD,
and control cases were made in accordance with estab-
lished criteria as described previously [41,42]. Diagnoses
of PD/Lewy Body Dementia [43], ALS [44], and tauopa-
thy [45-47] were also made based on established criteria.
Antibodies
In-house SEPT11 antibody (rabbit polyclonal) was raised
against keyhole limpet hemocyanin (KLH)-conjugated
peptide AVAVGRPSNEELRN at the extreme N-terminus
of the protein. Serum from the immunized rabbit was
tested by immunoblot and affinity-purified on a column
using the immunizing peptide. Commercially available
primary antibodies used in these studies were septin 11
(N-15; Santa Cruz Biotechnology, Santa Cruz CA) and
glial fibrillary acidic protein (DAKO, Carpinteria CA).
DNA Constructs
The full-length SEPT11 coding sequence (nucleotides 1-
1287, encoding amino acids 1-429) was amplified by
PCR from a commercial expression plasmid (Origene,
Rockville MD; Clone ID TC113610) using forward pri-
mer 5’-AGCTGCGTCTAGAATGGCCGTGGCCGT
GGG-3’ and reverse primer 5’-ATACGATATTTCTA-
GAACTGCAAAAGCAGGTGAATG-3’.T h eP C Rp r o -
ducts were digested and cloned into the pcDNA3.1-HA
expression vector downstream of the two-HA motifs
(peptide YPYDVDYA). The N-terminal HA expression
vectors were confirmed by DNA sequencing (Agencourt
Bioscience Corporation, Beverly MA).
Sequential Biochemical Fractionation
Sequential extractions were performed as previously
described [23] with buffers containing 1% Triton X-100,
1% N-Lauroyl-sarcosine (sarkosyl), and finally 7M urea/
2M thiourea. Generally, the protein yield in urea sam-
ples during sequential extraction was approximately 2%
of the starting material.
Protein Identification and Quantification by LC-MS/MS
XIC-based label-free quantitative proteomics on pooled
urea-soluble fractions was performed as previously
described [23]. For quantitative proteomics with CDIT,
HEK293 cells were cultured in DMEM (deficient in L-
Lysine and L-Arginine) supplemented with 2% dialyzed
fetal calf serum (Invitrogen) as described [48]. For stable
isotopic labeling, heavy forms L-Arginine and L-Lysine
were added (Arg10/Lys8, Cambridge Isotope Labora-
tories) to a final concentration of 0.13 mM. Excess pro-
line was added at 200 mg/L to block the conversion of
arginine to proline. Prior to SDS PAGE, 10 μg of heavy
labeled HEK whole cell lysate was added to 10 μgo f
unlabeled urea fraction from 4 pooled FTLD-U or con-
trol cases. The mixed (light and heavy) samples were
reduced with 10 mM DTT, and resolved on a 10% poly-
acrylamide SDS gel. After staining with Coomassie blue,
each gel lane was cut into five gel bands, and bands
were subjected to in-gel digestion (12.5 μg/ml trypsin).
Extracted peptides were analyzed via LC-MS/MS as
described previously [23]. To compare medium and
heavy labeled samples, database searches were modified
to include static modifications of +4.02511 on Lys and
+6.02013 on Arg, and dynamic modifications of
+3.98909 on Lys and +3.98814 on Arg to account for
mass difference between medium and heavy labeled
peptides. Quantitative pair-wise comparisons between
FTLD-U and control using the internal standard were
carried out as described previously [21,31,49].
Quantitative analysis of SEPT11 by targeted proteomics
For targeted proteomics and peptide mapping of
SEPT11, metabolically heavy-labeled HEK 293 cells were
transfected with tagged HA-SEPT11 constructs and har-
vested. The cell lysate alone (for peptide mapping) or
mixed with urea extracts from 4 pooled FTLD-U cases
was analyzed by LC-MS/MS in a data-independent MS/
MS mode to specifically identify and fragment ions cor-
responding to five pre-selected SEPT11 peptides (Addi-
tional File 6). Quantitative analysis was performed with
non-transfected heavy-labeled HEK 293 cell lysate as
internal standards. The labeled cells were spiked into
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and 4 pooled control cases. Samples were then resolved
by SDS-PAGE, and the gel piece corresponding to 40-60
kDa in each sample was subjected to trypsin in-gel
digestion. We then specifically quantified MS/MS ion
pairs for SEPT11 peptides AAAQLLQSQAQQS-
GAQQTK and FESDPATHNEPGVR.
Immunohistochemistry
Paraffin-embedded sections of hippocampus and frontal
cortex (8 μm thick) were deparaffinized and microwaved
in citrate buffer (0.01 M, pH 6) for 10 minutes. After
cooling to room temperature for 1 hour, sections were
rinsed and endogenous peroxidase activity was blocked
with 3% hydrogen peroxide at 40°C. Sections were then
incubated with normal goat serum for 15 minutes at 40°
C, followed by primary antibody (diluted in 1% BSA)
overnight at 4°C. The following day, sections were incu-
bated with biotinylated goat secondary antibody for 30
minutes at 37°C, and finally with avidin-biotin peroxi-
dase complex (Vector Laboratories) for 60 minutes at
37°C. 3,3’-Diaminobenzidine (DAB) was used as the
chromogen for color development and was followed
with hematoxylin counterstain.
Scoring of SEPT11 Immunoreactivity
Scoring of specific SEPT11 immunoreactivity in paraf-
fin-embedded sections of frontal cortex was done in a
blinded fashion by three independent raters. Scoring
was limited to superficial cortical layers (layers 2-3) and
included only thread-like structures not directly asso-
ciated with glial nuclei or processes. Astrocytic SEPT11-
staining was specifically excluded and was, therefore,
not evaluated. Staining was scored as negative (0; no
immunoreactivity), equivocal (1; very few threads), posi-
tive (2; threads common throughout superficial layers or
showing patchy dense distribution), or very positive (3;
threads densely distributed throughout superficial
layers). A consensus score was determined for each of
the cases examined, and typically corresponded to the
median score of the three scorers. In rare cases where
the three scorers differed by more than 1 point, cases
were re-evaluated in the presence of all three scorers. In
analyses, samples scored as negative or equivocal were
grouped together as “Low Presence of SEPT11 Threads,”
while samples scored as positive or very positive were
grouped together as “High Presence of SEPT11
Threads.” We considered age of onset, age at death,
post-mortem interval, disease duration, tissue quality,
and tissue volume as potential confounders for statistical
analyses. However, none of these parameters was signifi-
cantly associated with predicting the presence or
absence of SEPT11 threads. Thus, statistical compari-
sons were conducted using Fisher’s exact test.
Western Blotting
Immunoblotting was performed according to standard
procedures as described previously [49]. Notably, acquired
data were analyzed with GraphPad Prism 4.0 software (La
Jolla, CA) and statistical significance was determined by
unpaired two-tailed Student’s t test with a = 0.05. For pre-
absorption studies of SEPT11, primary antibodies were
preincubated with 100× molar excess of the antigen over-
night at 4°C before incubation with the blot.
Additional material
Additional file 1: Separation of pooled urea samples by SDS-PAGE
for proteomic analysis. (a) SDS-PAGE gel of urea fractions extracted
from AD, FTLD-U, and control pooled frontal cortex homogenates (10
cases each). (b) SDS-PAGE gel of 4 pooled FTLD-U or 4 pooled control
samples after addition of heavy labeled cell lysate. The gels were stained
with Coomassie Blue G-250 and gel lanes were excised in 5 pieces as
indicated (F1-F5 or C1-C5).
Additional file 2: Statistical evaluation and filtering of label-free
proteomics data. (a) Abundance ratios for FTLD-U/Control comparison
were transformed (logarithmic base 2) and plotted with each point
corresponding to the number of proteins in 0.3 unit windows (black
line). A Gaussian curve was subsequently fitted to the data (red line) and
used to determine significance levels for protein change. (b) Fitted
normal distributions for all possible pair-wise comparisons. Statistical
means, standard deviations, and regression coefficients are presented in
Additional File 3.
Additional file 3: Statistical data for fitted normal distributions.
Table detailing the specific properties of each fitted normal distribution
used for proteomic data analysis.
Additional file 4: Statistical evaluation and filtering of CDIT
proteomics data. Abundance ratios for FTLD-U/Control comparison
were transformed (logarithmic base 2) and plotted with each point
corresponding to the number of proteins in 0.4 unit windows (black
line). A Gaussian curve was subsequently fitted to the data (red line) and
used to determine significance levels for protein change.
Additional file 5: Peptide map of SEPT11. Amino acid sequence of full
length SEPT11 (429 aa) marked with peptides identified in shotgun
proteomics approaches (solid underline), mapped unique peptides in
targeted proteomics (red color), peptides quantified using targeted
proteomics (bold), and immunizing peptide used in development of in-
house SEPT11 rabbit polyclonal antibody (dotted underline).
Additional file 6: SEPT11 peptides selected for targeted proteomics.
Table detailing properties of SEPT11 peptides selected for targeted
proteomics.
Additional file 7: Assessment of SEPT11 in detergent-soluble
fractions by immunoblotting. Triton X-100 (a) and Sarkosyl (b) fractions
extracted from frontal cortex samples of individual FTLD-U and control
cases were immunoblotted with an N-terminus specific rabbit polyclonal
SEPT11 antibody. While full-length SEPT11 (49 kDa) is abundant in both
detergent-soluble fractions, the low molecular weight fragments noted in
the urea fractions (Figure 3) were decreased or absent in these fractions.
The band noted at ~40 kDa is non-specific as determined by
preabsorption studies using the immunizing peptide.
Additional file 8: Individual Case Demographic and Scoring
Information. Table detailing specific demographic data and scoring
results for all cases analyzed by immunohistochemistry.
List of Abbreviations
FTLD: frontotemporal lobar degeneration; FTLD-U: frontotemporal lobar
degeneration with ubiquitinated inclusions; LC-MS/MS: liquid
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